{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T21:28:39Z","timestamp":1790630919038,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T00:00:00Z","timestamp":1661126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis Plus"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.athplu.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,8,28]],"date-time":"2022-08-28T12:24:53Z","timestamp":1661689493000},"page":"32-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group)"],"prefix":"10.1016","volume":"50","author":[{"given":"Manuel Od\u00edn","family":"De los R\u00edos-Ibarra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Leiva-Pons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humberto","family":"Rodr\u00edguez-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Antonio","family":"Alcocer-Gamba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cort\u00e9s-Lawrenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida Mar\u00eda","family":"Vizca\u00edno-Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Barrag\u00e1n-Luna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio Iv\u00e1n","family":"Farjat-Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis R.","family":"Virgen-Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Padilla-Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Pavia-L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique C.","family":"Morales-Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie C.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-8388","authenticated-orcid":false,"given":"Leslie Marisol","family":"Lugo-Gavidia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.athplu.2022.08.002_bib1","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2022.08.002_bib2","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2022.08.002_bib3","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2022.08.002_bib4","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.athplu.2022.08.002_bib5","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2022.08.002_bib6","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)","volume":"41","author":"Mach","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2022.08.002_bib7","unstructured":"Carrillo-Larco, RM, Benites-Moya, CJ, Anza-Ramirez, C, et\u00a0al., A systematic review of population-based studies on lipid profiles in Latin America and the Caribbean."},{"key":"10.1016\/j.athplu.2022.08.002_bib8","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.atherosclerosis.2021.08.035","article-title":"Lipid-lowering therapy use in primary and secondary care in Central and Eastern Europe: DA VINCI observational study","volume":"334","author":"Vrablik","year":"2021","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2022.08.002_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232845","article-title":"30-year trends in major cardiovascular risk factors in the Czech population, Czech MONICA and Czech post-MONICA, 1985 - 2016\/17","volume":"15","author":"C\u00edfkov\u00e1","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.athplu.2022.08.002_bib10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.phrs.2018.12.002","article-title":"Characteristics of lipid profile and effectiveness of management of dyslipidaemia in patients with acute coronary syndromes - data from the TERCET registry with 19,287 patients","volume":"139","author":"Dyrbus","year":"2019","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.athplu.2022.08.002_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries--Findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.athplu.2022.08.002_bib12","article-title":"Lipid treatment and goal attainment characteristics among persons with atherosclerotic cardiovascular disease in the United States","volume":"1","author":"Klimchak","year":"2020","journal-title":"Am J Prev Cardiol"},{"key":"10.1016\/j.athplu.2022.08.002_bib13","doi-asserted-by":"crossref","first-page":"633","DOI":"10.21037\/cdt.2017.04.06","article-title":"The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention","volume":"7","author":"Kotseva","year":"2017","journal-title":"Cardiovasc Diagn Ther"},{"key":"10.1016\/j.athplu.2022.08.002_bib14","article-title":"Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational Research Programme EUROASPIRE V survey in 16 European countries","author":"Kotseva","year":"2020","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2022.08.002_bib15","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.athplu.2022.08.002_bib16","volume":"vol. 2016","author":"Kashef","year":"2016"},{"key":"10.1016\/j.athplu.2022.08.002_bib17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","year":"1998","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2022.08.002_bib18","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2022.08.002_bib19","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3949\/ccjm.71.8.609","article-title":"Lessons from the PROVE-IT trial. Higher dose of potent statin better for high-risk patients","volume":"71","author":"Khush","year":"2004","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.athplu.2022.08.002_bib20","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/CIRCULATIONAHA.109.906479","volume":"121","author":"Mora","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2022.08.002_bib21","first-page":"353","article-title":"Plaque REgression with cholesterol absorption inhibitor or synthesis inhibitor evaluated by IntraVascular UltraSound (PRECISE-IVUS trial): study protocol for a randomized controlled trial","volume":"66","author":"Tsujita","year":"2015","journal-title":"J\u00a0Cardiol"},{"key":"10.1016\/j.athplu.2022.08.002_bib22","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2022.08.002_bib23","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2022.08.002_bib24","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2022.08.002_bib25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2022.08.002_bib26","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1161\/CIRCRESAHA.118.312782","article-title":"Statin toxicity","volume":"124","author":"Ward","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.athplu.2022.08.002_bib28","series-title":"Nota tecnica Estadisticas de defunciones registradas en Mexico 2020","year":"2021"},{"issue":"Suppl","key":"10.1016\/j.athplu.2022.08.002_bib29","article-title":"Stent for Life Initiative: leading example in building STEMI systems of care in emerging countries","volume":"10","author":"Kaifoszova","year":"2014","journal-title":"EuroIntervention"},{"key":"10.1016\/j.athplu.2022.08.002_bib30","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1136\/bjsports-2014-094306","article-title":"Even a low-dose of moderate-to-vigorous physical activity reduces mortality by 22% in adults aged \u226560 years: a systematic review and meta-analysis","volume":"49","author":"Hupin","year":"2015","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.athplu.2022.08.002_bib31","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000000510","article-title":"Dietary fats and cardiovascular disease: a presidential advisory from the American heart association","volume":"136","author":"Sacks","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2022.08.002_bib32","doi-asserted-by":"crossref","first-page":"f6879","DOI":"10.1136\/bmj.f6879","article-title":"Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis","volume":"347","author":"Threapleton","year":"2013","journal-title":"Bmj"},{"key":"10.1016\/j.athplu.2022.08.002_bib33","doi-asserted-by":"crossref","first-page":"g4490","DOI":"10.1136\/bmj.g4490","article-title":"Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies","volume":"349","author":"Wang","year":"2014","journal-title":"Bmj"},{"key":"10.1016\/j.athplu.2022.08.002_bib34","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","article-title":"Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts","volume":"378","author":"Estruch","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.athplu.2022.08.002_bib35","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3945\/ajcn.2010.29673","article-title":"Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis","volume":"92","author":"Sofi","year":"2010","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.athplu.2022.08.002_bib36","volume":"vol. 9","author":"Mart\u00ednez-Gonz\u00e1lez","year":"2017"},{"key":"10.1016\/j.athplu.2022.08.002_bib37","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1161\/01.CIR.99.6.779","article-title":"Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study","volume":"99","author":"de Lorgeril","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.athplu.2022.08.002_bib38","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.athplu.2022.08.002_bib39","volume":"vol. 9","author":"M-V","year":"2021"},{"key":"10.1016\/j.athplu.2022.08.002_bib40","first-page":"168","article-title":"Practical recommendations for the management of cardiovascular risk associated with atherogenic dyslipidemia, with special attention to residual risk. Spanish adaptation of a European Consensus of Experts","volume":"29","year":"2017","journal-title":"Cl\u00edn Invest Arterioscler"},{"key":"10.1016\/j.athplu.2022.08.002_bib41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.arteri.2015.12.004","article-title":"[The role of atherogenic dyslipidaemia in clinical practice guidelines]","volume":"28","author":"Pedro-Botet","year":"2016","journal-title":"Cl\u00edn Invest Arterioscler"},{"key":"10.1016\/j.athplu.2022.08.002_bib42","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ijcard.2017.05.059","volume":"243","author":"Ponte-Negretti","year":"2017","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.athplu.2022.08.002_bib43","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis Society","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.athplu.2022.08.002_bib44","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jacc.2021.06.011","article-title":"ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American college of cardiology solution set oversight committee","volume":"78","author":"Virani","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.athplu.2022.08.002_bib45","first-page":"61","article-title":"Triglyceride-Rich lipoproteins: their role in atherosclerosis","volume":"74","author":"Castillo-N\u00fa\u00f1ez","year":"2022","journal-title":"Rev Invest Clin"}],"container-title":["Atherosclerosis Plus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089522000463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667089522000463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T08:44:11Z","timestamp":1763023451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667089522000463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":44,"alternative-id":["S2667089522000463"],"URL":"https:\/\/doi.org\/10.1016\/j.athplu.2022.08.002","relation":{},"ISSN":["2667-0895"],"issn-type":[{"value":"2667-0895","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk stratification and lipid evaluation in mexican patients, evidence of lipid and cardiovascular analysis in REMECAR. The mexican registry of cardiovascular diseases (REMECAR group)","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis Plus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.athplu.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}